Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Exp Hematol. 2014 Sep 3;42(12):1022–1030.e1. doi: 10.1016/j.exphem.2014.08.004

Figure 4. CALM-AF10 leukemia cells are sensitive to deferoxamine (DFO) and cytarabine.

Figure 4

(A) CalmHET CALM-AF10 leukemia cell lines (1, 2, 3) were exposed to varying concentrations DFO and the number of viable cells was measured by flow cytometry after 3 days. Four independent experiments were performed for CALM-AF10 #3, three independent experiments were performed for CALM-AF10 #1, and 2 independent experiments were performed for CALM-AF10 #2. Each experiment was performed in triplicate. (B) CalmHET CALM-AF10 cells were exposed to varying concentrations of DFO in conjunction with varying concentrations of cytarabine. Viable cells were counted by flow cytometry after three days. The combined effect of DFO and cytarabine followed the line of additivity by isobolometric analysis. One representative cell line (CALM-AF10 #3) of two total tested is shown. (Please see supplementary data for isobolometric analysis of CALM-AF10 #3).